Esther Rajavelu
Stock Analyst at UBS
(0.68)
# 4,024
Out of 5,056 analysts
26
Total ratings
46.15%
Success rate
-22.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $72.67 | -36.70% | 4 | Aug 12, 2025 | |
| APLT Applied Therapeutics | Downgrades: Neutral | $13 → $2 | $0.91 | +119.76% | 3 | Dec 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $17.52 | +82.65% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $452.74 | -52.51% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $33.53 | +117.72% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $7.95 | +1,271.07% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $25.13 | +39.28% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $136.71 | +66.78% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $41.42 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $22.28 | -41.65% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.68 | +495.24% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $72.67
Upside: -36.70%
Applied Therapeutics
Dec 2, 2024
Downgrades: Neutral
Price Target: $13 → $2
Current: $0.91
Upside: +119.76%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $17.52
Upside: +82.65%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $452.74
Upside: -52.51%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $33.53
Upside: +117.72%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $7.95
Upside: +1,271.07%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $25.13
Upside: +39.28%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $136.71
Upside: +66.78%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $41.42
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $22.28
Upside: -41.65%
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $1.68
Upside: +495.24%